Safer Warfarin Treatment (CYKOWAR)
Status
Conditions
Treatments
Details and patient eligibility
About
The study is a national multicenter prospective observational study, including 200 patients. The main purpose of this study is to explore in more detail the influence of genetic variability (CYP enzymes and vitamin K dependent proteins) and dietary vitamin K status on warfarin dosing, clinical effect and adverse events with emphasis on the initial phase of treatment. The hypothesis is that genetic variability concerning CYP enzymes and vitamin K dependent proteins predict dosing and adverse events during warfarin treatment. The main aim is to individualize warfarin therapy and establish a treatment algorithm based on genotype and dietary vitamin K status to make the anticoagulation therapy with warfarin more secure.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Caucasian
- >18 years of age
- included in the study at the onset of warfarin treatment
- target INR (2-3 for atrial fibrillation, vein thrombosis, pulmonary embolism and 2.5-3.5 for prosthetic heart valves)
- standard indications for warfarin treatment
Exclusion criteria
- Non-caucasian
- Clinical significant liver affection
- Heart failure, NYHA class III-IV
- Non-compliant - not able to accomplish protocol demands
- Not able to give informed consent
- Long-term antibiotic therapy
- Malabsorption conditions and inflammatory bowel disease
Trial design
200 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal